Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252
Phase of Trial: Phase II
Latest Information Update: 15 Jul 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms SALVO
- 23 Apr 2018 Planned End Date changed from 1 Feb 2020 to 1 Apr 2021.
- 23 Apr 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Apr 2019.
- 19 Oct 2017 Status changed from not yet recruiting to recruiting.